logo
Derrick Brown named new assistant Albany city manager

Derrick Brown named new assistant Albany city manager

Yahoo28-03-2025

ALBANY – Albany City Manager Terrell Jacobs announced Thursday that Derrick Brown will become the city's new assistant city manager for utility administration.
The position opened at the end of January when former Assistant City Manager Yvette Fields retired from the role.
Brown brings a wealth of knowledge to the position, city officials said in a news release. He has more than 32 years of manufacturing, accounting, business management, and leadership experience, having served in roles of increasing responsibility.
A Monroe Comprehensive High School graduate, Brown earned a bachelor of accounting degree from Albany State University and a master of manufacturing management degree from Kettering University, formerly known as GMI Engineering and Management Institute.
In his most recent role as chief financial officer for the city of Albany, Brown and his team have successfully managed a budget of more than $318 million. For 14 consecutive years and counting, the finance team has earned the 'Certificate of Achievement for Excellence in Financial Reporting' from the Government Finance Officers Association. The team also earned the coveted 'Distinguished Budget Presentation Award' for Fiscal Year 2025 from the Government Finance Officers Association.
Brown is also a Certified Retirement Plan Fiduciary, awarded by the Georgia Association of Public Plan Trustees.
'Having achieved this level of success in his previous roles, I have no doubt Mr. Brown will continue to excel and make significant contributions on behalf of the city of Albany as he leads Administrative Services, the Department of Community and Economic Development, Facilities Management, Fleet Management, the Recreation and Parks Department, Technology and Communications, the Public Information Office and the Business Development Office,' Jacobs said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rockford-area homeowners aren't selling. Here's why:
Rockford-area homeowners aren't selling. Here's why:

Yahoo

timean hour ago

  • Yahoo

Rockford-area homeowners aren't selling. Here's why:

ROCKFORD, Ill. (WTVO) — Winnebago, Boone, and Ogle counties' inventory of available homes reached an all-time low in April, with only 141 properties for sale. 'If we took every house currently on the market, the entire stock would sell out in less than 13days, that's how low inventory has reached,' said Conor Brown, CEO, Northwest Illinois Alliance of Realtors. The realty group said the low inventory could be traced back to the 2008 housing crisis, which reduced new home construction, which plummeted again during the COVID-19 pandemic and has yet to rebound. Among the reasons the agency cited: Current homeowners are locked into historic, pre-pandemic low interest rates on their mortgage loans and are unable or unwilling to move. Or, if they do, they're moving directly into a new home, resulting in no net gain to the number of available homes. According to the Bank of America, 60% of current homeowners and prospective buyers are hesitating about buying a new home, due to high interest rates on a new mortgage. According to FreddieMac, the average nationwide mortgage rate is 6.73%. 'More than eight in 10 homeowners had an interest rate lower than 6% as of the third quarter of 2024,' Brown said. 'More than half had a rate below 4%. Many current homeowners don't want to give up their 3% interest rate for 7%. That's helping keep a tight lid on the market. With homeowners staying put, that means fewer existing homes for sale and fewer choices for homebuyers.' Year-over-year housing sales volume increased for the 7th year in a row, with 311 properties sold in April, 7.2% more than the 290 sold last April. Realtors say 2025 could be the first time in four years that annual sales have risen if current trends continue, with 977 homes sold in the first four months of 2024, compared to the 1,071 sold in the same time frame this year. The average home in Rockford is selling in just 18 days, the agency said. , Rockford ranked as the hottest housing market in the U.S. in January 2025 according to . According to the report, homes in Rockford, which list for a median price of $242,000, spend just 43 days on the market, compared to the national average of 70. The national median listing price of a home is $424,900, according to the report. Last year, Rockford ranked as America's top housing market in a evaluation. In 2013, one-third of Rockford's mortgages were underwater, worth less than what was owed on them. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

AstraZeneca sues Utah attorney general over new drug pricing law
AstraZeneca sues Utah attorney general over new drug pricing law

Yahoo

time2 hours ago

  • Yahoo

AstraZeneca sues Utah attorney general over new drug pricing law

AstraZeneca, a major pharmaceutical company, has sued Utah's Attorney General Derek Brown over a recently passed state law allowing for lower pricing in pharmacies. The lawsuit concerns how SB69, passed during the 2025 state legislative session, deals with Section 340B of the federal Public Health Service Act. The suit was filed in May in the U.S. District Court of the District of Utah. The lawsuit argues that SB69 violates federal law by expanding the 340B drug discount program to unlimited pharmacies. The 340B drug discount program is designed to provide pricing benefits to specific eligible health care entities. It requires pharmaceutical manufacturers to offer products at steeply discounted rates for a specific list of entities. 'Because such price controls can disincentivize innovation and destabilize markets, Congress carefully crafted Section 340B and limited participation in the program to fifteen — and only fifteen — types of covered entities," per the lawsuit. It also points out that for-profit pharmacy chains, such as CVS and Walgreens, were not included in the list of covered entities. AstraZeneca's suit seeks for an order declaring that SB69 violates federal law and is unconstitutional. It also seeks to stop Brown and Utah Insurance Commissioner Jon Pike from enforcing SB69 against AstraZeneca in any manner. The Utah Attorney General's Office said Friday it had no comment on the lawsuit. SB69, which was sponsored by Sen. Evan Vickers, R-Cedar City, defines terms related to the 340B drug discount program and prohibits pharmaceutical manufacturers from setting certain restrictions. Under the law, manufacturers cannot prohibit or restrict pharmacies from contracting with 340B entities. They also cannot deny these 340B entities access to specific drugs. 'Apparently dissatisfied with the scope of federal law, the State of Utah has enacted a statute seeking to achieve under state law precisely the same result that federal courts have resoundingly rejected,' per the suit. 'The state law requires pharmaceutical manufacturers to offer 340B-discounted pricing for sales at an unlimited number of contract pharmacies.' The suit says that SB69 extends Section 340B price caps beyond the scope of the federal program, requiring manufacturers to make discounted drugs available for sale at any and all pharmacies 'authorized by a 340B entity to receive the drug.' It alleges that the law extends the discounts to new categories of transactions that are not covered by the program, thus conflicting with federal law requirements. The suit argues that the law conflicts with federal law, specifically court rulings that 'make clear that the federal 340B statute does not obligate manufacturers to deliver discounted drugs to unlimited contract pharmacies." According to the suit, SB69 also violates federal patent law, which 'prohibits states from regulating the price of patented goods.' 'It requires manufacturers like AstraZeneca to offer steeply discounted prices for the sale of their patented drugs, thereby extending federal price caps to an additional category of patented drug sales (contract pharmacy sales) that federal courts have held fall outside of the 340B program. It also argues that SB69 violates the Contracts Clause of the U.S. Constitution and the Constitution's takings clause.

Josh Brown says Tesla investor base doesn't care about Musk-Trump feud: 'I wouldn't bet against it'
Josh Brown says Tesla investor base doesn't care about Musk-Trump feud: 'I wouldn't bet against it'

CNBC

time4 hours ago

  • CNBC

Josh Brown says Tesla investor base doesn't care about Musk-Trump feud: 'I wouldn't bet against it'

Ritholtz Wealth Management CEO Josh Brown said Tesla investors will look past the online feud between Elon Musk and President Donald Trump that led to a sell-off on Thursday. Musk, the CEO of Tesla and a key supporter of Trump during his election, exchanged barbs with the president online on Thursday — a shocking turn given their previous allegiance. Shares of the electric vehicle maker tumbled more than 14% on Thursday, but gained more than 5% in midday trading on Friday. "The drama on Twitter is hilarious. Of course, everyone's having a great time," Brown said on CNBC's "Halftime Report," using the former name for social media platform X. "But I think the real story here is the investor base in Tesla literally doesn't care about anything." TSLA 5D mountain Tesla, 5-day Brown pointed out that Tesla is losing market share in most key areas. However, he said investors have decided to think of the company as a robot and automation name with some artificial intelligence work rather than an electric vehicle maker. Investors think "the car sales are only important insofar as they get us to the robotaxi, which is the next trillion-dollar idea," Brown said. "I don't believe that, but that's what the market believes." Brown called the name a "nothing-matters stock," noting that it trades at 120-times earnings. He said investors may use Thursday's sell-off as a chance to buy on a dip. Shares are now down more than 25% in 2025. "It's just incredible how faithful this shareholder base is," Brown said. "I wouldn't bet against it." All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. INVESTING INVOLVES RISK. EXAMPLES OF ANALYSIS CONTAINED IN THIS ARTICLE ARE ONLY EXAMPLES. THE VIEWS AND OPINIONS EXPRESSED ARE THOSE OF THE CONTRIBUTORS AND DO NOT NECESSARILY REFLECT THE OFFICIAL POLICY OR POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC. JOSH BROWN IS THE CEO OF RITHOLTZ WEALTH MANAGEMENT AND MAY MAINTAIN A SECURITY POSITION IN THE SECURITIES DISCUSSED. ASSUMPTIONS MADE WITHIN THE ANALYSIS ARE NOT REFLECTIVE OF THE POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC" TO THE END OF OR OUR DISCLOSURE. Click here for the full disclaimer.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store